Directed share issue in Calliditas Therapeutics AB — SEK 324 million

Carnegie acted as joint global co-ordinator and joint bookrunner in the directed share issue of 2,400,000 new shares at a subscription price of SEK 135 per share. Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
August 2021.